ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $3.50 Average Target Price from Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have received a consensus rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $3.50.

ALXO has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of ALX Oncology from a “sell” rating to a “hold” rating in a research note on Monday, December 22nd. Jefferies Financial Group initiated coverage on ALX Oncology in a report on Thursday, November 13th. They set a “buy” rating and a $4.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ALX Oncology in a research report on Wednesday, January 21st.

Institutional Trading of ALX Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALXO. Invesco Ltd. purchased a new stake in shares of ALX Oncology during the 1st quarter worth approximately $46,000. Bridgeway Capital Management LLC acquired a new stake in ALX Oncology during the 3rd quarter worth $66,000. AQR Capital Management LLC lifted its position in ALX Oncology by 183.6% in the first quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock valued at $74,000 after acquiring an additional 77,065 shares during the last quarter. Jane Street Group LLC acquired a new position in ALX Oncology in the second quarter valued at $84,000. Finally, Acadian Asset Management LLC grew its holdings in shares of ALX Oncology by 16.8% during the first quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock worth $806,000 after purchasing an additional 186,883 shares during the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Stock Performance

Shares of ALX Oncology stock opened at $1.57 on Tuesday. The business has a 50-day simple moving average of $1.36 and a 200-day simple moving average of $1.25. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.40 and a current ratio of 2.40. ALX Oncology has a one year low of $0.40 and a one year high of $2.27. The company has a market cap of $85.13 million, a PE ratio of -0.77 and a beta of 0.51.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings results on Friday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.04). On average, equities research analysts forecast that ALX Oncology will post -2.76 EPS for the current fiscal year.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.